Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003501-90

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to determine the activity of AG-013736 in advanced non-small cell lung cancer as measured by the overall response rate, complete response (CR) and partial response (PR) by RECIST.


Critère d'inclusion

  • Second-or Later Line treatment in patients with advanced Non-Small Cell lung Cancer

Liens